牛磺熊去氧膽酸 TUDCA × 肝硬化
Direct human evidence for TUDCA supplements in liver cirrhosis is essentially a single small, low-quality double-blind RCT (PMID 23592128, n=18, 26 weeks) that improved surrogate liver biochemistry (ALT/AST/ALP, albumin) but showed NO significant change in serum fibrosis markers and only one patient with histological improvement; no trial has demonstrated any hard-outcome benefit (mortality, decompensation, transplant-free survival).
Direct human evidence for TUDCA supplements in liver cirrhosis is essentially a single small, low-quality double-blind RCT (PMID 23592128, n=18, 26 weeks) that improved surrogate liver biochemistry (ALT/AST/ALP, albumin) but showed NO significant change in serum fibrosis markers and only one patient with histological improvement; no trial has demonstrated any hard-outcome benefit (mortality, decompensation, transplant-free survival). The other TUDCA RCTs cited are in PBC (PMID 8674405) and HCV hepatitis (PMID 9840118), not established cirrhosis, and the fibrosis-regression data (PMID 40299532) are preclinical rat/cell models only. No institution endorses the consumer TUDCA supplement for cirrhosis: NIH ODS, NCCIH, Mayo Clinic, Cleveland Clinic and Harvard Health have no TUDCA content, and AASLD/EASL support only the structurally related prescription drug UDCA for PBC, which is a distinct cholestatic indication and not TUDCA-supplement-for-cirrhosis evidence. The totality is best graded C: a small amount of low-quality direct evidence exists with a positive surrogate signal, but it is far too limited, uncertain and surrogate-bound to support a stronger grade, while a hard counter-finding (no fibrosis benefit) prevents calling it merely insufficient (U).
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.485
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群（PTT FITNESS/MuscleBeach/Doctor-Info/medstudent、Dcard、Mobile01、痞客邦）幾乎沒有「牛磺熊去氧膽酸(TUDCA)用於肝硬化」的真實使用討論；肝硬化串多談西醫追蹤、肝指數、史他汀與保肝迷思，TUDCA 多出現在 iHerb/Dr.Berg/海外代購等商品頁與業配型介紹，並非鄉民實測心得。
無共識（社群缺乏將 TUDCA 用於肝硬化的鄉民實測；TUDCA 在台灣以海外進口保健品形式存在，討論集中於健身族『護肝/降肝指數』取向，鮮少針對肝硬化此一臨床診斷）
- 戒酒
- 限鈉飲食與利尿劑治療腹水
- 治療潛在病因（抗病毒治療、代謝管理）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-liver-cirrhosis-INT-tudca-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "牛磺熊去氧膽酸能改善肝硬化",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}